Clinical trials: Patients With Major Depressive Disorder
Depression, Dementia
RCT of Brain Longitudinal Biomarker Study (OPT-Neuro RCT)
The purpose of this study is to assess which antidepressants work the best in older adults who have treatment-resistant depression (TRD), and to test whether treatment-resistant late life depression is associated with declines in…
- Conditions
- Depression, Dementia, Mild Cognitive Impairment, Treatment Resistant Depression
- Trial name
- ONR (NCT05531591)
- Testing
- Aripiprazole Augmentation, Bupropion Augmentation, Switch to bupropion
- Where
- 4 sites in United States, Canada
- Volunteers
- 87 people
- Sponsor
- Centre for Addiction and Mental Health
Major Depressive Disorder, Major Depressive Disorder w/ Psychotic Features
Risks for Insulin Resistance and Metabolic Syndrome Between Major Depressive Disorder (MDD) or MDD With Psychotic Features
Studies have shown that people with certain disorders have an increased risk of developing a condition called Metabolic Syndrome (MS).
- Conditions
- Major Depressive Disorder, Major Depressive Disorder w/ Psychotic Features, Metabolic Syndrome
- Trial name
- NCT01310140
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
Adjunct Minocyline in Treatment-resistant Depression
This study examines the antidepressant efficacy of minocycline as an adjunct to an antidepressant standard treatment (AD-ST), for patients with unipolar major depressive disorder (MDD).
- Trial name
- Mino-TRD (NCT02456948)
- Testing
- Minocycline
- Where
- 9 sites in Germany
- Volunteers
- 168 people
- Sponsor
- Charite University, Berlin, Germany
Major Depressive Disorder
A Study to Evaluate the Safety and Efficacy of TS-121 as an Adjunctive Treatment for Major Depressive Disorder
The purpose of this study is to evaluate the safety, tolerability, and efficacy of TS-121 as an adjunctive treatment for patients with major depressive disorder with an inadequate response to current antidepressant Treatment…
- Trial name
- NCT03093025
- Testing
- TS-121 10 mg, TS-121 50 mg
- Where
- 22 sites in United States
- Volunteers
- 51 people
- Sponsor
- Taisho Pharmaceutical R&D Inc.
Major Depressive Disorder
A Study to Investigate Evoked Potentials as Markers of Ketamine-induced Cortical Plasticity in Patients With Major Depressive Disorder
To evaluate if somatosensory evoked potentials (SEPs) and motor evoked potentials (MEPs) obtained with electroencephalography (EEG) and electromyography (EMG) can be used to detect changes in cortical plasticity in responders to…
- Trial name
- NCT01957410
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder
Aripiprazole Augmentation Versus Switching to Different Class of Antidepressants in Major Depressive Disorder
The objective of this study is to compare the efficacy and safety of aripiprazole as adjunctive therapy versus switching to different class of antidepressants for treating major depressive disorder partially or minimally…
- Trial name
- NCT01488266
- Testing
- Aripiprazole, switching to different class of antidepressant
- Where
- 2 sites in South Korea, Taiwan
- Volunteers
- 90 people
- Sponsor
- Korea University
Major Depressive Disorder
Bear Bile Pill as add-on the Treatment of MDD
This is a single-center, double blind, randomized, placebo-controlled, parallel group study of bear bile pill, as add-on therapy in MDD patients conducted in Shang Hai Mental Health Center.
- Trial name
- NCT04509882
- Testing
- bear bile pill
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Shanghai Mental Health Center
Major Depressive Disorder
A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder
This trial is a 14 week, randomized, double-blind, placebo controlled study, to assess the safety and efficacy of aripiprazole as adjunctive treatment to an ongoing antidepressant treatment in patients with Major Depressive…
- Trial name
- NCT00095823
- Testing
- Antidepressant + Aripiprazole
- Where
- 20 sites in United States
- Volunteers
- 1,200 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder, Traumatic Brain Injury
Adapted Cognitive Behavioral Treatment for Depression in Patients With Moderate to Severe Traumatic Brain Injury
Cognitive behavioral therapy for major depressive disorder (MDD) was adapted for individuals with moderate to severe traumatic brain injury (TBI) (CBT-TBI). A structured, treatment manual was developed.
- Trial name
- NCT03307070
- Testing
- Cognitive Behavioral Therapy for individuals with TBI, Waitlist Control
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Massachusetts General Hospital
Treatment Resistant Depression
Deciphering Principles of Network Dynamics Underlying Depression Symptom Severity From Multi-day Intracranial Recordings in Patients With Major Depression
Major depressive disorder (MDD) is common and causes significant disability world-wide. While typically responsive to medications and therapy, there remain a subset of patients who are treatment resistant.
- Trial name
- NCT06953362
- Testing
- Direct Neural Electrical Stimulation
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of California, San Francisco
Major Depressive Disorder, Irritable Bowel Syndrome
Neurocognitive Effects of FMT in MDD Patients With and Without IBS
This study is a phase 2/3 open-label controlled trial (CT) in which adults with Major Depressive Disorder (MDD) and adults who have MDD plus comorbid Inflammatory Bowel Syndrome (IBS) will be assigned to either receive oral Fecal…
- Trial name
- NCT05174273
- Testing
- Fecal Microbiota Transplantation
- Where
- Canada
- Volunteers
- 133 people
- Sponsor
- Valerie Taylor
Major Depressive Disorder
Early Prediction of Fluoxetine Response
The purpose of this study is to identify what degree of symptom changes during the early weeks could be used to predict eventual nonresponse at week 6 among depressive inpatients taking fluoxetine.
- Trial name
- NCT01075529
- Testing
- fluoxetine
- Where
- Taiwan
- Volunteers
- 140 people
- Sponsor
- Kaohsiung Kai-Suan Psychiatric Hospital
Major Depressive Disorder
Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive Disorder
This is an interventional, parallel arm assignment treatment study in individuals with Major Depressive Disorder (MDD). Each individual will be treated with a single dose of pimavanserin or placebo plus a single dose of…
- Trial name
- NCT06592833
- Testing
- Psilocybin, Pimavanserin
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Major Depressive Disorder
Efficacy and Safety Study of Seroquel SR in the Treatment of Major Depressive Disorder
The primary purpose of this study is to evaluate whether treatment with (SEROQUEL SR) quetiapine fumarate sustained release (SR) for 9 weeks compared to placebo will improve depressive symptoms in elderly patients with major…
- Trial name
- NCT00388973
- Testing
- Quetiapine
- Where
- 43 sites in United States, Argentina and 4 more
- Volunteers
- 338 people
- Sponsor
- AstraZeneca
Atopic Dermatitis
The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatitis
This study aims to assess the impact of dupilumab on the mental health and quality of life of moderate-to-severe Atopic Dermatitis (AD) patients.
- Trial name
- DERMIND-AD (NCT07467564)
- Testing
- Dupilumab
- Where
- 7 sites in Qatar, Saudi Arabia and 1 more
- Volunteers
- 184 people
- Sponsor
- Sanofi
Depressive Disorder, Depressive Disorder, Major
Brain Derived Neurotropic Factor Response to Aerobic Exercise Intensity in Depressive Patients.
Acute aerobic exercise improves affective stats in patients with mental illnesses. Brain derived neurotropic factor (BDNF) may be a biological mechanism that contributes to the affective benefits.
- Trial name
- NCT02741622
- Testing
- High aerobic intensity training (HIT), Long slow distance training (LSD)
- Where
- Norway
- Volunteers
- 21 people
- Sponsor
- St. Olavs Hospital
Major Depressive Disorder
Medical and Psychiatric Co-Morbidity Among Treatment Resistant Patients With Major Depression Disorder
Assessing psychiatric and physiological co-morbidity in TRD and non-TRD patients
- Trial name
- NCT00229398
- Sponsor
- Sheba Medical Center
Depression
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
The purpose of the study is to evaluate the efficacy of study drug (BMS-820836) as compared with continued Duloxetine/Escitalopram in the treatment of patients with treatment resistant depression (TRD).
- Trial name
- NCT01369095
- Testing
- Duloxetine, Escitalopram, BMS-820836
- Where
- 93 sites in United States, Argentina and 10 more
- Volunteers
- 976 people
- Sponsor
- Bristol-Myers Squibb
Major Depressive Disorder (MDD)
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
This will be a multicenter, randomized, double-blind study designed to assess the efficacy, safety and tolerability of an oral Aripiprazole/Escitalopram combination therapy in participants with MDD who have demonstrated an…
- Trial name
- NCT01111552
- Testing
- Escitalopram, Aripiprazole
- Where
- 60 sites in United States, Australia and 5 more
- Volunteers
- 237 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder, Irritability
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
To explore the anti-impulsive and anti-aggressive properties of brexpiprazole in a naturalistic setting of depressed patients with irritability.
- Trial name
- NCT01942785
- Testing
- Brexpiprazole
- Where
- 15 sites in United States
- Volunteers
- 55 people
- Sponsor
- H. Lundbeck A/S